2nd Apr 2025 13:03
(Alliance News) - Ondine Biomedical on Wednesday said that Steriwave, its nasal decolonization technology, has reduced infection rates in Mid Yorkshire Teaching NHS Trust's joint surgeries.
Following Mid Yorkshire's analysis from a six-month period, commissioned by Health Innovation Network Yorkshire & Humber and Ondine, Steriwave significantly reduced the combined rate of surgical site infection rates in elective hip and knee replacement surgeries by around 72%, from a baseline rate of 1.4% to 0.4%.
Steriwave is made by Vancouver, Canada-based company Ondine Biomedical Inc, which produces antimicrobial therapies. It is a non-invasive and painless nasal decolonization treatment that uses a light-activated agent to destroy harmful pathogens, including bacteria, viruses, and fungi, in the nose.
Ondine said the treatment is effective immediately, taking less than five minutes and involves applying a propriety photosensitive agent to each nostril with a nasal swab, followed by illumination with a specific wavelength of red light for five minutes.
Chief Executive Officer of Ondine Carolyn Cross said: "We anticipate that MYTT's early adoption of this technology in the UK will serve as an influential example for healthcare institutions globally, promoting the pursuit of improved patient outcomes and better patient throughput while mitigating the risks associated with antimicrobial resistance."
Ondine also said that after conducting a new health economic analysis, the York Health Economics Consortium found that Mid Yorkshire's use of Steriwave is cost-saving for hip and knee replacement surgery.
There was also a reduction from 2.3% to zero in the results from knee replacements.
The YHEC health economic analysis showed that in a standardised cohort of 1,000 people, Steriwave prevents a total of 9.8 surgical site infections more than standardised care alone. According to Ondine, this saves GBP2,869 and reduces the overall number of hospital bed days by 139.
Survey data from Mid Yorkshire also revealed that there have been high levels of satisfaction with Steriwave among staff and patients.
Ondine shares were down 3.5% at 9.41 pence in London on Wednesday.
By Olivia Mason-Myhill, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Ondine Biomed